Alessandro Meduri

Dr. Alessandro Meduri

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
FFFrancesco Freni
Francesco Freni
AMAlessandro Meduri
Alessandro Meduri
FGFrancesco Gazia
Francesco Gazia
VNViviana Nicastro
Viviana Nicastro
Cosimo GallettiCosimo Galletti
Cosimo Galletti
FGFrancesco Galletti
Francesco Galletti

19 November 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAlessandro Meduri
Alessandro Meduri
GOGiovanni William Oliverio
Giovanni William Oliverio
GMGiuseppe Mancuso
Giuseppe Mancuso
AGAngela Giuffrida
Angela Giuffrida
CGClaudio Guarneri
Claudio Guarneri
PAPasquale Aragona
Pasquale Aragona
To evaluate the ocular manifestation in patients hospitalized with coronavirus disease 2019 (COVID-19) and to search for the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tears. This study was conducted in 29 hospitalized patients who were admitted to the COVID center at the Policlinic Hospital of the University of Messina, Italy. All patients underwent an ophthalmologic assessment comprising a Standardized Patient Evaluation of Eye Dryness (SPEED) questionnaire, anterior segment, and the ocular surface examination of both eyes using a portable slit lamp. The Schirmer I test was performed, and the filter paper strip was used to search for the presence of SARS-CoV-2 on the ocular surface by real-time quantitative polymerase chain reaction (RT-qPCR). A total of 10 patients reported ocular symptoms; in particular, four reported eye burning, three reported foreign body sensation, and three reported tearing. Moreover, seven patients presented conjunctival hyperemia and/or chemosis, eleven patients presented blepharitis signs such as lid margin hyperemia and/or telangiectasia, crusted eyelashes, and meibomian orifices alterations. Tear analysis did not reveal the presence of SARS-CoV-2. Ocular symptoms are common in patients with COVID-19; although, tear analysis did not reveal the presence of SARS-CoV-2.

Verified
Journal Article
Open access
PDF file
Davide BorroniDavide Borroni
Davide Borroni
APAndreu Paytuví
Andreu Paytuví
WSWalter Sanseverino
Walter Sanseverino
CHCarmen Gomez Huertas
Carmen Gomez Huertas
PBPaola Bonci
Paola Bonci
OCon behalf of LUCY Consortium
on behalf of LUCY Consortium
Purpose: This study aims to explore and characterize healthy eye microbiota. Methods: Healthy subjects older than 18 years were selected for this descriptive cross-sectional study. Samples were collected with an eSwab with 1 mL of Liquid Amies Medium (Copan Brescia, Italy). Following DNA extraction, libraries preparation, and amplification, PCR products were purified and end-repaired for barcode ligation. Libraries were pooled to a final concentration of 26 pM. Template preparation was performed with Ion Chef according to Ion 510, Ion 520, and Ion 530 Kit-Chef protocol. Sequencing of the amplicon libraries was carried out on a 520 or 530 chip using the Ion Torrent S5 system (Thermo Fisher; Waltham, MA, USA). Raw reads were analyzed with GAIA (v 2.02). Results: Healthy eye microbiota is a low-diversity microbiome. The vast majority of the 137 analyzed samples were highly enriched with Staphylococcus, whereas only in a few of them, other genera such as Bacillus, Pseudomonas, and Corynebacterium predominate. We found an average of 88 genera with an average Shannon index of 0.65. Conclusion: We identified nine different ECSTs. A better understanding of healthy eye microbiota has the potential to improve disease diagnosis and personalized regimens to promote health.

1 January 2021 in Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
AMAlessandro Meduri
Alessandro Meduri
GOGiovanni William Oliverio
Giovanni William Oliverio
LTLuigi Trombetta
Luigi Trombetta
MGMarta Giordano
Marta Giordano
LILeandro Inferrera
Leandro Inferrera
CTCostantino John Trombetta
Costantino John Trombetta
Purpose . To evaluate efficacy and safety of intravitreal dexamethasone 0.7 mg implant in treatment‐naïve DME patients and to assess the utility of OCT structural biomarkers as predictors of functional response after treatment. Methods . Thirty‐nine eyes of 39 diabetic patients with center involving DME were enrolled. Best‐corrected visual acuity (BCVA) and SS‐OCT (DRI SS‐OCT Triton, Topcon, Japan) to evaluate central retinal thickness (CRT), serous retinal detachment (SRD), intraretinal cysts (IRC), number of hyper‐reflective spots (HRS), integrity of the ellipsoid zone (EZ), disorganization of the inner retinal layers (DRIL), vitreomacular adhesion (VMA), vitreomacular traction (VMT), and posterior vitreous detachment (PVD) were evaluated at baseline and at 3, 6, and 12 months after treatment. Multiple logistic analysis was performed to evaluate the possible OCT biomarker as predictive factors for final visual acuity improvement at the end of treatment. Results . At 12 months after treatment, the mean BCVA improved from 51.6 ± 17.5 to 56.9 ± 17.3 ETDRS letters ( p = 0.03). Furthermore, there were statistically significant changes in CRT, IRC, HRS, and SRD. Nineteen patients presented a >10‐letters improvement in BCVA; the presence of SRD at baseline was a predictor of good functional treatment response at 12 months (OR 2.1; 95% C.I. 1.2–4.9; p = 0.001) as well as the presence of EZ integrity preoperatively (OR 1.3; 95% C.I. 0.5–2.4; p = 0.001) and the absence of vitreoretinal interface alteration (OR 1.1; 95% C.I. 0.3–2.3; p = 0.02). No significant changes in the IOP and lens status were observed throughout the follow‐up period. Conclusion . This study empathized the importance of structural biomarkers as predictors of favorable response and confirmed the efficacy and safety of intravitreal dexamethasone implant in treatment‐naïve DME patients showing a better functional response in the presence of SRD integrity of EZ and absence of vitreoretinal alterations.

20 December 2008 in Ophthalmic Research
Verified
Journal Article
Closed access
AMAlessandro Meduri
Alessandro Meduri
PGPier Luigi Grenga
Pier Luigi Grenga
LSLucia Scorolli
Lucia Scorolli
PCPiero Ceruti
Piero Ceruti
GFGiuseppe Ferreri
Giuseppe Ferreri
Aims: To evaluate the efficacy of cysteine oral supplements in corneal wound healing after photorefractive keratectomy (PRK). Methods: A total of 200 eyes (100 patients) underwent PRK. We divided patients into 2 groups; each group was composed of 50 patients (100 eyes). Group 1 patients were assigned to use oral L-cysteine, with a daily dose of 200 mg (100-mg pills to be taken twice a day) for a duration of 14 days, starting from the week preceding the operation; the patients in group 2 were used as a control, and received the oral supplementation of 40-mg placebo pills to be taken twice a day for a duration of 14 days, starting from the week preceding the operation. Results: All the eyes of patients treated with cysteine oral supplements showed shorter times to re-epithelization than the eyes of the control group. The mean time of corneal wound healing observed in group 1 was 102 ± 15 h, compared to an average of 159 ± 9 h in group 2. Conclusion: Our research showed that oral cysteine supplementation, in a daily dose of 200 mg, reduces mean corneal wound healing time in patients after PRK.

5 February 2020 in Journal of Craniofacial Surgery
Verified
Journal Article
Closed access
BGBruno Galletti
Bruno Galletti
FFFrancesco Freni
Francesco Freni
AMAlessandro Meduri
Alessandro Meduri
GOGiovanni William Oliverio
Giovanni William Oliverio
GSGiuseppe Alberto Signorino
Giuseppe Alberto Signorino
FGFrancesco Galletti
Francesco Galletti
The authors present their experience about clinical evidences that include patients with an untreated diabetes who developed rhino-orbito-cerebral mucormycosis (ROCM). They were treated with endoscopic sinus surgery and medical treatment with intravenous, intradural therapy, and sinus washes with amphotericin B. The ROCM is a disease with a rapid evolution and an increase in mortality rate, especially if the fungus enters the cranial cavity. Therefore, it would be necessary in all diabetic patients with sinus symptoms, headaches, visual changes, suspect a mucormycosis, and perform a careful radiology assessment and a nasal endoscopy. Often, despite an early diagnosis and rapid treatment for ROCM, it is not possible to stem the disease, which ends with the patient's death.